We are studying a combination of two medications for patients with brain metastases from non-small cell lung cancer. The goal is to see how well this treatment works in reducing tumor size and improving patient outcomes.
We are testing a new method of delivering a PD-1 antibody directly into the spinal fluid for patients with metastatic solid tumors and leptomeningeal disease. The study aims to determine the safe dosage and its potential impact on survival.
We are studying how tacrolimus affects blood sugar levels in patients on hemodialysis waiting for a kidney transplant. This research may help improve diabetes management in these patients.
We are studying whether botulinum toxin can help reduce pain and improve function in people with degenerative rotator cuff disease. Participants will be monitored for effectiveness and any side effects over three months.
We are testing a new drug combination for patients newly diagnosed with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. The study aims to see if this combination improves survival without disease progression compared to standard treatments.
We are studying the effects of regorafenib in patients with advanced melanoma who have already been treated. The goal is to see if it helps control the disease better when combined with other therapies.
We are studying a new oncolytic virus treatment combined with chemotherapy for patients with melanoma. This trial aims to see if this combination can improve treatment outcomes.
We are studying the PAGETEX device to see if it helps control Extra-Mammary Paget's Disease of the vulva. The trial will also look at pain levels, quality of life, and patient satisfaction during treatment.
We are studying whether avoiding anticoagulation or using a specific procedure helps improve health outcomes for patients after an intracerebral hemorrhage. We also aim to identify brain markers that may indicate future bleeding risks.
We are studying whether a 30-week caffeine treatment can help improve thinking and memory in people with early to moderate Alzheimer's disease. This trial compares the effects of caffeine to a placebo to see if it makes a difference.
We are studying the effectiveness and safety of a new treatment combination for elderly patients with newly diagnosed multiple myeloma. This research aims to find better ways to manage the disease.
We are exploring a new treatment combining light therapy and immunotherapy for patients with malignant pleural mesothelioma. The study aims to assess safety, effectiveness, and impact on quality of life.
We are studying whether talazoparib can help keep mesothelioma from progressing after initial chemotherapy. This trial is for patients with advanced pleural or peritoneal mesothelioma.
We are studying the effects of vericiguat in patients with heart failure and reduced ejection fraction. The goal is to see if it can lower heart failure markers compared to a placebo.
We are studying whether a standard or reduced dose of amiodarone is more effective in keeping a normal heart rhythm after cardioversion in patients with persistent atrial fibrillation. We will also assess any side effects and how genetics may affect treatment.
We are studying whether adding perianal infiltration during the RAFAELO® procedure helps reduce pain after treatment for hemorrhoids. This trial aims to improve comfort for patients undergoing this procedure.
We are studying the safety and effectiveness of ginisortamab combined with standard treatments for metastatic pancreatic cancer. This trial will help us understand how well it works and its potential side effects.
We are evaluating a new treatment for adults with Immunoglobulin A Nephropathy to see if it helps reduce protein in urine and preserve kidney function. The study also looks at its effects on slowing kidney failure and improving fatigue.
We are testing a new imaging agent to see how well it can identify certain immune cells in patients with non-small cell lung cancer. This may help improve imaging techniques for better diagnosis and treatment planning.
We are studying a new treatment combination for patients with newly diagnosed multiple myeloma who cannot have a transplant. The goal is to see if it works better than a standard treatment option.